NASDAQ:QDEL QuidelOrtho (QDEL) Stock Price, News & Analysis → Collapse of the Petrodollar (From Colonial Metals) (Ad) Free QDEL Stock Alerts $42.61 -1.01 (-2.32%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$41.52▼$43.7250-Day Range$38.26▼$49.0052-Week Range$37.78▼$90.45Volume1.08 million shsAverage Volume923,399 shsMarket Capitalization$2.85 billionP/E RatioN/ADividend YieldN/APrice Target$59.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get QuidelOrtho alerts: Email Address QuidelOrtho MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside38.5% Upside$59.00 Price TargetShort InterestHealthy4.68% of Shares Sold ShortDividend StrengthN/ASustainability-2.61Upright™ Environmental ScoreNews Sentiment0.10Based on 19 Articles This WeekInsider TradingAcquiring Shares$99,652 Bought Last QuarterProj. Earnings Growth68.61%From $2.23 to $3.76 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.88 out of 5 starsMedical Sector39th out of 925 stocksDiagnostic Substances Industry1st out of 12 stocks 4.0 Analyst's Opinion Consensus RatingQuidelOrtho has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 2 buy ratings, 3 hold ratings, and 2 sell ratings.Amount of Analyst CoverageQuidelOrtho has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about QuidelOrtho's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.68% of the outstanding shares of QuidelOrtho have been sold short.Short Interest Ratio / Days to CoverQuidelOrtho has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in QuidelOrtho has recently increased by 15.50%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldQuidelOrtho does not currently pay a dividend.Dividend GrowthQuidelOrtho does not have a long track record of dividend growth. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreQuidelOrtho has received a 49.48% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Sexually transmitted diseases quick tests", "Lactose intolerance quick tests", and "Respiratory tract infection tests" products. See details.Environmental SustainabilityThe Environmental Impact score for QuidelOrtho is -2.61. Previous Next 2.3 News and Social Media Coverage News SentimentQuidelOrtho has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for QuidelOrtho this week, compared to 5 articles on an average week.MarketBeat Follows5 people have added QuidelOrtho to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, QuidelOrtho insiders have bought more of their company's stock than they have sold. Specifically, they have bought $99,652.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.00% of the stock of QuidelOrtho is held by insiders.Percentage Held by Institutions99.00% of the stock of QuidelOrtho is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about QuidelOrtho's insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for QuidelOrtho are expected to grow by 68.61% in the coming year, from $2.23 to $3.76 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of QuidelOrtho is -1.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of QuidelOrtho is -1.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQuidelOrtho has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about QuidelOrtho's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. About QuidelOrtho Stock (NASDAQ:QDEL)QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.Read More QDEL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart QDEL Stock News HeadlinesMay 10, 2024 | prnewswire.comROSEN, NATIONAL TRIAL COUNSEL, Encourages QuidelOrtho Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - QDELMay 10, 2024 | prnewswire.comInvestors in QuidelOrtho Corporation f/k/a Quidel Corporation Should Contact The Gross Law Firm Before June 11, 2024 to Discuss Your Rights - QDELMay 12, 2024 | Colonial Metals (Ad)Collapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar. For one main reason.May 9, 2024 | markets.businessinsider.comQuidelOrtho’s Uncertain Outlook Prompts Sell Rating Amidst Guidance Suspension and Revenue ChallengesMay 9, 2024 | finance.yahoo.comQuidelOrtho Corporation (NASDAQ:QDEL) Q1 2024 Earnings Call TranscriptMay 9, 2024 | prnewswire.comQDEL Investors Have Opportunity to Lead QuidelOrtho Corporation Securities Fraud LawsuitMay 9, 2024 | finance.yahoo.comQuidelOrtho Corp (QDEL) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges with ...May 8, 2024 | investorplace.comQDEL Stock Earnings: QuidelOrtho Misses EPS, Beats Revenue for Q1 2024May 12, 2024 | Colonial Metals (Ad)Collapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar. For one main reason.May 8, 2024 | chron.comQuidelOrtho: Q1 Earnings SnapshotMay 8, 2024 | finance.yahoo.comQuidelOrtho Reports First Quarter 2024 Financial ResultsMay 8, 2024 | seekingalpha.comQuidelOrtho Corporation 2024 Q1 - Results - Earnings Call PresentationMay 8, 2024 | prnewswire.comLevi & Korsinsky Notifies Shareholders of QuidelOrtho Corporation f/k/a Quidel Corporation(QDEL) of a Class Action Lawsuit and an Upcoming DeadlineMay 7, 2024 | prnewswire.comInvestors who lost money on QuidelOrtho Corporation f/k/a Quidel Corporation (QDEL) should contact The Gross Law Firm about pending Class Action - QDELMay 6, 2024 | prnewswire.comQuidelOrtho Corporation f/k/a Quidel Corporation Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 11, 2024 to Discuss Your Rights - QDELMay 5, 2024 | markets.businessinsider.comONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of QuidelOrthoMay 5, 2024 | msn.comQuidelOrtho names Brian Blaser as CEOMay 3, 2024 | markets.businessinsider.comSHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the FirmMay 3, 2024 | prnewswire.comROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages QuidelOrtho Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - QDELMay 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of QuidelOrthoMay 3, 2024 | prnewswire.comQDEL Investors Have Opportunity to Lead QuidelOrtho Corporation Securities Fraud LawsuitMay 3, 2024 | prnewswire.comClass Action Filed Against QuidelOrtho Corporation f/k/a Quidel Corporation (QDEL) Seeking Recovery for Investors - Contact The Gross Law FirmMay 2, 2024 | finance.yahoo.comQuidelOrtho Appoints Brian J. Blaser as President and Chief Executive OfficerMay 2, 2024 | businesswire.comQuidelOrtho Appoints Brian J. Blaser as President and Chief Executive OfficerMay 1, 2024 | prnewswire.comQDEL Investors Have Opportunity to Lead QuidelOrtho Corporation Securities Fraud LawsuitMay 1, 2024 | prnewswire.comINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against QuidelOrtho Corporation and Encourages Investors with Losses to Contact the FirmApril 30, 2024 | markets.businessinsider.comDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of QuidelOrthoSee More Headlines Receive QDEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for QuidelOrtho and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/13/2024Today5/11/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryHealth Care Supplies Current SymbolNASDAQ:QDEL CUSIP74838J10 CIK353569 Webwww.quidel.com Phone(800) 874-1517Fax858-453-4338Employees7,100Year Founded1979Price Target and Rating Average Stock Price Target$59.00 High Stock Price Target$76.00 Low Stock Price Target$37.00 Potential Upside/Downside+38.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($26.39) Trailing P/E RatioN/A Forward P/E Ratio19.11 P/E GrowthN/ANet Income$-10,100,000.00 Net Margins-61.65% Pretax Margin-65.95% Return on Equity3.96% Return on Assets2.24% Debt Debt-to-Equity Ratio0.68 Current Ratio1.55 Quick Ratio0.88 Sales & Book Value Annual Sales$3.00 billion Price / Sales0.95 Cash Flow$10.73 per share Price / Cash Flow3.97 Book Value$49.46 per share Price / Book0.86Miscellaneous Outstanding Shares66,880,000Free Float66,210,000Market Cap$2.85 billion OptionableOptionable Beta0.17 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Michael S. Iskra (Age 54)Interim CEO, Executive VP & Chief Commercial Officer Comp: $870.93kMr. Robert J. Bujarski J.D. (Age 55)Interim President, Executive VP & COO Comp: $961.26kMr. Joseph M. Busky CPA (Age 56)Chief Financial Officer Comp: $890.63kDr. Werner Kroll Ph.D. (Age 67)Senior Vice President of Research & Development Comp: $1.03MMs. Louise M. Brandy (Age 65)Chief Information Officer Ruben ArguetaDirector of Investor RelationsMs. Michelle A. Hodges J.D. (Age 61)Senior VP, General Counsel & Corporate Secretary Comp: $1.8MMr. William J. Ferenczy (Age 68)Point of Care Business Unit Leader Ms. Tamara A. Ranalli (Age 51)Molecular Diagnostics Business Unit Leader More ExecutivesKey CompetitorsNeogenNASDAQ:NEOGCelldex TherapeuticsNASDAQ:CLDXIntellia TherapeuticsNASDAQ:NTLAMyriad GeneticsNASDAQ:MYGNMeridian BioscienceNASDAQ:VIVOView All CompetitorsInsiders & InstitutionsEdgestream Partners L.P.Bought 19,175 shares on 5/11/2024Ownership: 0.029%Vanguard Group Inc.Bought 37,733 shares on 5/10/2024Ownership: 7.295%Private Management Group Inc.Bought 260,508 shares on 5/9/2024Ownership: 0.685%Blair William & Co. ILBought 1,059 shares on 5/9/2024Ownership: 0.075%State Board of Administration of Florida Retirement SystemSold 7,051 shares on 5/9/2024Ownership: 0.066%View All Insider TransactionsView All Institutional Transactions QDEL Stock Analysis - Frequently Asked Questions Should I buy or sell QuidelOrtho stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for QuidelOrtho in the last twelve months. There are currently 2 sell ratings, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" QDEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in QDEL, but not buy additional shares or sell existing shares. View QDEL analyst ratings or view top-rated stocks. What is QuidelOrtho's stock price target for 2024? 7 brokerages have issued 12 month price objectives for QuidelOrtho's shares. Their QDEL share price targets range from $37.00 to $76.00. On average, they predict the company's share price to reach $59.00 in the next year. This suggests a possible upside of 38.5% from the stock's current price. View analysts price targets for QDEL or view top-rated stocks among Wall Street analysts. How have QDEL shares performed in 2024? QuidelOrtho's stock was trading at $73.70 at the start of the year. Since then, QDEL shares have decreased by 42.2% and is now trading at $42.61. View the best growth stocks for 2024 here. When is QuidelOrtho's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our QDEL earnings forecast. How were QuidelOrtho's earnings last quarter? QuidelOrtho Co. (NASDAQ:QDEL) released its quarterly earnings results on Tuesday, February, 13th. The company reported $1.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.01 by $0.84. The firm had revenue of $742.60 million for the quarter, compared to the consensus estimate of $796.91 million. QuidelOrtho had a positive trailing twelve-month return on equity of 3.96% and a negative net margin of 61.65%. The firm's revenue was down 14.3% on a year-over-year basis. During the same period last year, the firm earned $1.74 EPS. What ETFs hold QuidelOrtho's stock? ETFs with the largest weight of QuidelOrtho (NASDAQ:QDEL) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM), First Trust Health Care AlphaDEX Fund (FXH), SPDR S&P Health Care Equipment ETF (XHE), ROBO Global Healthcare Technology and Innovation ETF (HTEC), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD).iShares U.S. Medical Devices ETF (IHI). What guidance has QuidelOrtho issued on next quarter's earnings? QuidelOrtho issued an update on its FY 2024 earnings guidance on Tuesday, February, 13th. The company provided EPS guidance of 2.400-3.070 for the period, compared to the consensus EPS estimate of 5.070. The company issued revenue guidance of $2.8 billion-$3.1 billion, compared to the consensus revenue estimate of $3.0 billion. What is Doug Bryant's approval rating as QuidelOrtho's CEO? 47 employees have rated QuidelOrtho Chief Executive Officer Doug Bryant on Glassdoor.com. Doug Bryant has an approval rating of 76% among the company's employees. What other stocks do shareholders of QuidelOrtho own? Based on aggregate information from My MarketBeat watchlists, some companies that other QuidelOrtho investors own include NVIDIA (NVDA), DocuSign (DOCU), Tesla (TSLA), PayPal (PYPL), Shopify (SHOP), Block (SQ), Teladoc Health (TDOC), Netflix (NFLX), Advanced Micro Devices (AMD) and Zoom Video Communications (ZM). Who are QuidelOrtho's major shareholders? QuidelOrtho's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.30%), LSV Asset Management (1.13%), Private Management Group Inc. (0.68%), Leeward Investments LLC MA (0.33%), Principal Financial Group Inc. (0.28%) and Russell Investments Group Ltd. (0.21%). Insiders that own company stock include Charles P Slacik, Joseph M Busky and Mary Lake Ph D Polan. View institutional ownership trends. How do I buy shares of QuidelOrtho? Shares of QDEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:QDEL) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsGold Set to EXPLODE!Gold Safe ExchangeCollapse of the Petrodollar Colonial MetalsShocking: One AI startup's revenue could surge 4,735%Manward Press[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICHe Is Giving Away BitcoinCrypto Swap ProfitsGlobal crypto currency reset (41 major banks signed up)Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding QuidelOrtho Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.